Tag Archives: Pfizer&#039s

ACC: BMS, Pfizer's Eliquis tops warfarin in high-risk Afib subgroup

Pfizer and Bristol-Myers Squibb’s next-gen anticoagulant Eliquis has been stealing warfarin market share for years, but that doesn’t mean it’s slowing down. The drug now has new data showing it’s the safer option for a tough-to-treat group of atrial fibrillation patients. The companies pitted Eliquis against Vitamin K antagonists, such as warfarin, in certain Afib… Read More »